Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment
Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...
YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...
BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing
BioRay Pharmaceutical Co., Ltd. today announced the execution of a comprehensive license, supply, and commercialization...
IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea
IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...
GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD
GlaxoSmithKline plc (GSK, NYSE: GSK) and Empirico Ltd. today announced a global exclusive licence agreement...
WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of...
Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N
Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...
Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...
Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today released its third‑quarter 2025 financial results....
Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its third‑quarter 2025 financial results....
Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off...
Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its controlled subsidiary,...
Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...
SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...
Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China National...
Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer
China‑based Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has...
Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025
At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck,...
PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline
PolyMed Biopharmaceuticals Co., Ltd., a Chinese‑based, internationally‑oriented biopharma innovator, announced the successful closure of its...
NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5
The National Medical Products Administration (NMPA) today issued the “Measures for the Administration of Drug...
Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today...